HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.

Abstract
Targeting vascular endothelial growth factor (VEGF) pathway represents a successful strategy in the treatment of metastatic colorectal cancer (mCRC). Since the approval of the first antiangiogenic drug, the anti-VEGF monoclonal antibody bevacizumab, a number of other molecules have been tested in preliminary trials and are currently under investigation in phase III randomized studies. At present, no clinical tools are available to select patients more likely to benefit from VEGF pathway inhibitors nor to exclude those who are proner to suffer from specific adverse events, so that almost all mCRC patients are potentially candidate to receive an antiangiogenic-containing regimen. To overcome this substantial limit, a consistent aid is awaited by the identification of molecular tools of selection. Retrospective analyses and translational studies have been conducted and are currently ongoing to address this major question, investigating molecular, biological and genetic markers. This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity.
AuthorsFotios Loupakis, Guido Bocci, Giuseppe Pasqualetti, Lorenzo Fornaro, Lisa Salvatore, Chiara Cremolini, Gianluca Masi, Romano Danesi, Mario Del Tacca, Alfredo Falcone
JournalCurrent cancer drug targets (Curr Cancer Drug Targets) Vol. 10 Issue 1 Pg. 37-45 (Feb 2010) ISSN: 1873-5576 [Electronic] Netherlands
PMID20088795 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factors
  • bevacizumab
Topics
  • Adult
  • Aged
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Clinical Trials, Phase III as Topic
  • Colorectal Neoplasms (blood supply, drug therapy)
  • Humans
  • Neoplasm Metastasis
  • Neovascularization, Pathologic (drug therapy)
  • Patient Selection
  • Vascular Endothelial Growth Factors (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD